

ANSWER 1 OF 1 JAPIO (C) 2005 JPO on STN.
AN 2000-290197 JAPIO
TI COMPOSITION CONTAINING **MULTIFUNCTIONAL PROTEASE
INHIBITOR AS ACTIVE INGREDIENT**
IN IQBAL MOHAMED; DIEBOLD JAMES; SIMAN ROBERT; CHATTERJEE SANKAR; KAUER JAMES
C
PA CEPHALON INC
PI JP 2000290197 A 20001017 Heisei
AI JP 2000-2705 (JP20000002705 Heisei) 19951114
PRAI US 1994-337795 19941114
US 1995-464398 19950605
US 1995-552794 19951103
SO PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 2000

Also caplus, medline, cancerlit & Biocng.

ANSWER 1 OF 1 USPATFULL on STN
AN 2005:99056 USPATFULL
TI Methods of protein production in yeast
IN Barr, Philip J., Oakland, CA, UNITED STATES
Gibson, Helen L., Oakland, CA, UNITED STATES
PI US 2005084972 A1 20050421
AI US 2004-914863 A1 20040809 (10)
PRAI US 2003-493984P 20030808 (60)
DT Utility
FS APPLICATION
LREP Daniel M. Becker, c/o HELLER EHRMAN WHITE & MCAULIFFE LLP, 275
Middlefield Road, Menlo Park, CA, 94025, US
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2396

(FILE 'HOME' ENTERED AT 17:38:49 ON 17 AUG 2005)

FILE 'USPATFULL, JAPIO, EPFULL, PCTFULL, BIOENG' ENTERED AT 17:39:43 ON 17 AUG 2005

L1 1 S MULTIFUNCTIONAL PROTEASE INHIBITOR
L2 0 S L1 (A) SECRETORY LEUCOCYTE PROTEASE
L3 1 S FUSION PROTEIN (A) ALPHA 1-ANTITRYPSIN
L4 0 S FUSION PROTEIN (A) SECRETORY LEUCOCYTE PROTEASE INHIBITOR
L5 0 S FUSION PROTEIN (A) SLPI
L6 0 S FUSION PROTEASE INHIBITOR
L7 0 S FUSION (A) SERPIN
L8 0 S MULTIFUNCTIONAL SERINE PROTEASE INHIBITOR
L9 0 S MULTIFUNCTIONAL SERINE PROTEASE INHIBITOR
L10 1 S HYBRID PROTEASE INHIBITOR
L11 5185 S ALPHA 1-ANTITRYPSIN
L12 1 S L11 (A) FUSION PROTEIN
L13 13 S L11 (A) SLPI
L14 0 S L13 (A) FUSION
L15 1 S HYBRID SERPIN
L16 0 S SERPIN (A) FUSION PROTEIN
L17 0 S ALPHA 1-ANITRYPSIN (A) SLPI
L18 0 S ALPHA 1-ANITRYPSIN (A) TISSUE INHIBITOR
L19 0 S ALPHA 1-ANITRYPSIN (A) TISSUE METALLOPROTEASE INHIBITOR
L20 0 S HYBRID METALLOPROTEASE INHIBITOR
L21 0 S FUSION PROTEIN (A) METALLOPROTEASE INHIBITOR

FILE 'BIOENG' ENTERED AT 18:07:33 ON 17 AUG 2005

L22 0 S MULTIFUNCTIONAL PROTEASE INHIBITOR
L23 0 S FUSION PROTEASE INHIBITOR
L24 0 S FUSION PROTEIN (A) PROTEASE INHIBITOR
L25 0 S FUSION SERPIN
L26 380 S PROTEASE INHIBITOR
L27 0 S L6 (A) FUSION PROTEIN
L28 0 S L6 (A) HYBRID
L29 141 S L11
L30 0 S L21
L31 0 S L20
L32 0 S L19
L33 0 S L18
L34 0 S L17
L35 0 S L16
L36 0 S L15
L37 0 S L14
L38 0 S L13
L39 0 S L12
L40 141 S L11
L41 0 S L40 (A) FUSION PROTEIN

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:898699 CAPLUS

DN 141:374746

TI Modified procollagen α chain fusion protein and their uses in wound healing and fibrosis therapy

IN Kadler, Karl; Bulleid, Neil; Ashcroft, Gillian

PA The Victoria University of Manchester, UK

SO Brit. UK Pat. Appl., 59 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2400852	A1	20041027	GB 2003-24457	20031021
	WO 2004094472	A2	20041104	WO 2004-GB1719	20040421
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,				
	SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				
	TD, TG				

PRAI GB 2003-9064 A 20030422

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:402499 CAPLUS
 DN 115:2499
 ED Entered STN: 12 Jul 1991
 TI Recombinant **hybrid protease inhibitors** and
 their use
 IN Ringe, Dagmar
 PA Massachusetts Institute of Technology, USA
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 IC ICM C12N015-62
 ICS C12N015-15; C12P021-02; C07K007-00
 CC 3-4 (Biochemical Genetics)
 Section cross-reference(s): 7

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9100912	A1	19910124	WO 1990-US3769	19900703
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
PRAI	US 1989-376876	A	19890707		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9100912	ICM	C12N015-62
	ICS	C12N015-15; C12P021-02; C07K007-00

AB A highly specific hybrid protease inhibitor comprises a nonimmunogenic carrier polypeptide having an internal portion replaced/expanded with a synthetic peptide that specifically binds and inhibits a protease. The hybrid protease inhibitor also exhibits longer in vivo half-life than the synthetic peptide per se, which is desirable for clin. applications. Preparation of **hybrid protease inhibitors** that are inhibitory to elastase, chymotrypsin, trypsin, HIV protease, thrombin, and renin, resp., using interleukin-1 β as a nonimmunogenic carrier polypeptide are demonstrated.

ST recombinant hybrid protease inhibitor interleukin; elastase inhibitor recombinant hybrid; trypsin inhibitor recombinant hybrid; chymotrypsin inhibitor recombinant hybrid; HIV protease inhibitor recombinant hybrid; thrombin inhibitor recombinant hybrid; renin inhibitor recombinant hybrid

IT Escherichia coli
 (expression in, of hybrid protease inhibitor genes encoding interleukin 1- β -synthetic peptide fusion)

IT Molecular cloning
 (of hybrid nonimmunogenic protease inhibitor genes, in Escherichia coli)

IT Virus, animal
 (human immunodeficiency, protease of, hybrid inhibitor containing interleukin 1- β and synthetic inhibition site for inhibition of)

IT Lymphokines and Cytokines
 RL: BIOL (Biological study)
 (interleukin 1 β , hybrid protease inhibitor containing, as nonimmunogenic carrier)

IT 118071-38-8 118102-43-5 134371-49-6
 RL: PRP (Properties)
 (HIV protease recognition and inhibition site, synthetic, hybrid inhibitor containing interleukin 1- β and)

IT 134371-46-3
 RL: PRP (Properties)
 (chymotrypsin recognition and inhibition site, synthetic, hybrid inhibitor containing interleukin-1 β and)

IT 133793-06-3 134371-48-5
 RL: PRP (Properties)
 (elastase recognition and inhibition site, synthetic, hybrid inhibitor
 containing interleukin 1- β and)

IT 9002-04-4, Thrombin 9002-07-7, Trypsin 9004-06-2, Elastase
 9004-07-3, Chymotrypsin 9015-94-5, Renin, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor, interleukin 1- β nonimmunogenic carrier-synthetic
 peptide fusion as)

IT 37205-61-1, Protease inhibitor
 RL: PRP (Properties)
 (interleukin 1- β nonimmunogenic carrier-synthetic peptide fusion
 as, recombinant)

IT 75645-19-1 82252-55-9 134371-51-0 134371-52-1
 RL: PRP (Properties)
 (renin recognition and inhibition site, synthetic, hybrid inhibitor
 containing interleukin 1- β and)

IT 134371-50-9
 RL: PRP (Properties)
 (thrombin recognition and inhibition site, synthetic, hybrid inhibitor
 containing interleukin 1- β and)

IT 134371-47-4
 RL: PRP (Properties)
 (trypsin recognition and inhibition site, synthetic, hybrid inhibitor
 containing interleukin 1- β and)

=>